Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder

Wiener Klinische Wochenschrift

Volumn 111, Issue 11, 1999, Pages 439-442

  Zitterl, Werner ^a,e   Meszaros, Kurt ^a   Hornik, Kurt ^b   Twaroch, Teresa ^b   Dossenbach, Martin ^c   Zitterl Eglseer, Karin ^a   Zapotoczky, Hans Georg ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^c Eli Lilly Regional GmbH   (Austria)

^d Univ Klin für Psychiatrie   (Austria)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

Double blind; Fluoxetine; Obsessive compulsive disorder; Placebo

Indexed keywords

FLUOXETINE;

ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSION; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; AUSTRIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PERSONALITY ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0033522868     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Karno M, Golding JM, Sorenson SB, Burman MA (1988) The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 45: 1094-1099
2. Rasmussen SA, Tsuang MT (1986) Clinical characteristics and family history in DSM-III obsessive-compulsive disorder. Am J Psychiatry 143: 317-322
3. Clomipramine Collaborative Study Group (1991) Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 48: 730-738
4. Trethowan JWH, Scott PAL (1955) Chlorpromazine in obsessive compulsive and allied disorders. Lancet: 781-785
5. Orvin GH (1967) Treatment of the phobic obsessive compulsive patient with oxazepam, an improved benzodi-azepine compound. Psychosomatics 8: 278-280
6. Rao AV (1964) A controlled trial with valium in obsessive compulsive states. J Indian Med Assoc 42: 564-567
7. Insel TR, Murphy DL, Cohen RM, Atterman I, Kitts C, Linnoila M (1983) Obsessive compulsive disorder: a double blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 40: 605-612
8. Zohar J, Insel TR, Zohar-Kadouch RC, Murphy DL (1987) Serotonergic responsivity in obsessive-compulsive disorder. Arch Gen Psychiatry 44: 946-951
9. Perse TC, Greist JH, Jefferson JW, Rosenfeld R, Dar R (1987) Fluvoxamine treatment of obsessive compulsive disorder. Am J Psychiatry 144: 1543-1548
10. Chouinard G, Goodman W, Greist JH (1990) Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive compulsive disorder. Psychopharmacol Bull 26: 279-284
11. Cottraux J, Mollard E, Bouvard M, Marks I, Sluys M, Nury AM, et al (1990) A controlled study of fluvoxamine and exposure in obsessive compulsive disorder. Int Clin Psychopharmacol 5: 17-30
12. Goodman WK, Price LH, Delgado PL, Krystal JH, Nagy LM, Rasmussen SA, et al (1990) Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 47: 577-585
13. Greist JH (1991) Fluvoxamine treatment of obsessive-compulsive disorder. Presented at the 5th World Congress of Biological Psychiatry, Florence, Italy
14. Turner SM, Jacob RG, Beider DC, Himmelhoch J (1985) Fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 5: 207-212
15. Fontaine R, Chouinard G (1986) An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 6: 98-101
16. Jenike MA, Buttolph L, Baer L, Ricciardi J, Holland A (1989) Open trial of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 146: 909-911
17. Liebowitz MR, Hollander E, Schneier F, Campeas R, Hatterer J, Papp L, et al (1989) Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial. J Clin Psychopharmacol 9: 423-427
18. Montgomery SA, McIntrye A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, et al (1993) A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 3: 143-154
19. Tollefson G, Rampey Jr. AH, Potvin JH, Jenike MA, Rush AJ, Dominguez RA, et al. (1994) A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 51: 559-657
20. National Institute of Mental Health (1976) CGI: Clinical global impressions. In: Guy E (ed) ECDEU Assessment for Psychopharmacology, Rev. edn. NIMH, Rockville, MD, pp 217-222
21. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. (1989) The Yale-Brown obsessive compulsive scale. I. development, use and reliability. Arch Gen Psychiatry 46: 1006-1011
22. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al (1989) The Yale-Brown obsessive compulsive scale. II. Validity. Arch Gen Psychiatry 46: 1012-1016
23. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62
24. Ihaka R, Gentleman R (1996) A language for data analysis and graphics. J Comput Graphical Statistics 5: 299-314
25. Altamura AC, Montgomery SA, Wernicke JF (1988) The evidence for 20 mg a day of fluoxetine as the optimal daily dose in the treatment of depression. Br J Psychiatry 153: 109-112
26. Kasper S, Heßelman B, Wein W (1997) Erhaltungstherapie mit 20 mg Fluoxetin. Wien Klin Wochenschr 109: 197-201
27. Fulton B, McTavish D (1995) Fluoxetine: An overview of its pharmacodynamic and pharmacokinetic properties and review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drugs 3: 305-322
28. de Jonghe F, Swinkels JA (1992) The safety of antidepressants. Drugs 43: 40-47
29. Goodman WK, Kozak MJ, Liebowitz M, White KL (1996) Treatment of obsessive-compulsive disorder with fluvoxamine: A multi-center, double-blind placebo-controlled trial. Int Clin Psychopharmacol 11: 21-29